B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny

被引:158
作者
Anolik, Jennifer H. [1 ]
Friedberg, Jonathan W. [1 ]
Zheng, Bo [1 ]
Barnard, Jennifer [1 ]
Owen, Teresa [1 ]
Cushing, Emily [1 ]
Kelly, Jennifer [1 ]
Milner, Eric C. B. [1 ]
Fisher, Richard I. [1 ]
Sanz, Inaki [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, James P Wilmot Canc Ctr, Div Hematol Oncol,Dept Med Div Clin Immunol & Rhe, Rochester, NY 14642 USA
关键词
rituximab; B lymphocytes; transitional B cells; lymphoma;
D O I
10.1016/j.clim.2006.08.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The long-term immunologic effects of B cell depletion with rituximab and the characteristics of the reconstituting B cell pool in lymphoma patients are not well defined, despite the widespread usage of this therapy. Here we report that during the B cell reconstitution phase a majority of the peripheral blood B cells have an immature transitional phenotype (47.8% +/- 25.2% vs. 4.4% +/- 2.4% for normal controls, p < 0.0001), similar to what has been described during the original ontogeny of the immune system and following bone marrow transplantation. Moreover, the recovery of the CD27+ memory B cell pool was delayed compared to normal B cell ontogeny, remaining below normal controls at 1 year post-rituximab (4.4% +/- 3% vs. 31% +/- 7%, p < 0.0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 27 条
  • [1] Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    Anolik, JH
    Barnard, J
    Cappione, A
    Pugh-Bernard, AE
    Felgar, RE
    Looney, RJ
    Sanz, I
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3580 - 3590
  • [2] B lymphocyte reconstitution after hernatopoietic stem cell transplantation:: functional immaturity and slow recovery of memory CD27+ B cells
    Avanzini, MA
    Locatelli, F
    Dos Santos, C
    Maccario, R
    Lenta, E
    Oliveri, M
    [J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (04) : 480 - 486
  • [3] Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome
    Bohnhorst, JO
    Bjorgan, MB
    Thoen, JE
    Natvig, JB
    Thompson, KM
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (07) : 3610 - 3618
  • [4] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [5] Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity
    Cuss, AK
    Avery, DT
    Cannons, JL
    Yu, LJ
    Nichols, KE
    Shaw, PJ
    Tangye, SG
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (03) : 1506 - 1516
  • [6] Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma:: increased interferon-α/β-inducible gene expression, without significant toxicity
    Friedberg, JW
    Kim, H
    McCauley, M
    Hessel, EM
    Sims, P
    Fisher, DC
    Nadler, LM
    Coffman, RL
    Freedman, AS
    [J]. BLOOD, 2005, 105 (02) : 489 - 495
  • [7] FRIEDBERG JW, 2005, TARGETING CD20 FOLLI
  • [8] Single agent rituximab in patients with follicular or mantle cell lymphoma:: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:: a study of the Swiss Group for Clinical Cancer Research (SAKK)
    Ghielmini, A
    Rufibach, K
    Salles, G
    Leoncini-Franscini, L
    Léger-Falandry, C
    Cogliatti, S
    Fey, M
    Martinelli, G
    Stahel, R
    Lohri, A
    Ketterer, N
    Wernli, A
    Cerny, T
    Schmitz, SFH
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (10) : 1675 - 1682
  • [9] Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization
    Gokmen, E
    Raaphorst, FM
    Boldt, DH
    Teale, JM
    [J]. BLOOD, 1998, 92 (08) : 2802 - 2814
  • [10] Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
    Gordan, LN
    Grow, WB
    Pusateri, A
    Douglas, V
    Mendenhall, NP
    Lynch, JW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1096 - 1102